Immune Checkpoint Blockade (ICB) has reshaped cancer care and can deliver durable remission in malignancies such as melanoma and non-small cell lung cancer.

这项发表在《自然》上的研究，通过层层递进的逻辑，为我们解开了一个长期存在的谜题。它确立了“肠道-肿瘤轴”中T细胞可塑性的核心地位，提出了“抗原模拟”作为治疗策略的可行性，并强调了微生物种类的选择至关重要。

A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment. Publishing in Nature Immunology, ...

In a study published in the journal Biofunctional materials, researchers from the Wits Advanced Drug Delivery Platform (WADDP) Research Unit, Department of Pharmacy and Pharmacology, and the Division ...

Vaxiion Therapeutics Announces Completion of Phase 1a Dose Escalation and Initiation of a Phase 1b Dose Expansion Study for Intralesional Administration of VAX014 in Combination with PD-1 Directed ...

A landmark study headed by researchers at Yale School of Medicine and at Fred Hutchinson Cancer Center has revealed that autoantibodies (AAbs)—immune proteins traditionally associated with autoimmune ...

Phase 1b LANTERN clinical study is assessing tolododekin alfa, anchored IL-12 immunotherapy, in combination with anti PD-1/PD-L1 immune checkpoint blockade for treatment of non-small cell lung cancer ...

Phase 1 study of B440, an oral Bifidobacterium-engineered WT1 cancer vaccine, in patients with metastatic urothelial cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

Advancing racial representation in clinical trials: An analysis of 53 ASCO plenary and late-breaking abstracts using the DRIVE score. Facilitating meaningful patient involvement in the design and ...